Overview


According to FutureWise analysis the market for antibody drug conjugate in 2023 is US$ 10.50 billion, and is expected to reach US$ around 35 billion by 2031 at a CAGR of 19.6%.

Antibody-drug conjugates (ADCs) are highly targeted biopharmaceutical medications that combine monoclonal antibodies to recognize surface antigens-specific tumor cells with highly potent anti-cancer agents linked via a chemical linker. Antibody-drug conjugates are complex molecules that require careful attention to various components. The selection of an appropriate target, a mAb, cytotoxic payload, and how the antibody is linked to the load are critical determinants of the safety and effectiveness of ADCs. These targeted agents combine antibodies' unique and very sensitive targeting capabilities, allowing acute discrimination between healthy and cancerous tissues with the cell-killing ability of cytotoxic drugs.

Antibodies are glycoproteins generated by the body in response to foreign particles. A monoclonal antibody (mAb) is made by cloning a specific WBC or unique parent cell. Monoclonal antibodies have monovalent affinity, which means they bind to a specific molecular region or part of an antigen known as an epitope or antigenic determinant. Polyclonal antibodies bind to different epitopes produced by various antibody cell lineages. There are five higher animal types of immunoglobulins: IgG, IgM, IgA, IgE, and IgD. IgG is the most prevalent of all. Each IgG molecule consists of four polypeptide chains, including two heavy chains of 50 kDa and two light chains of 25 kDa, held together by four disulfide bridges.

FutureWise Market Research has published a report that provides an insightful analysis antibody drug conjugate market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, antibody drug conjugate market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Seattle Genetics
  • ImmunoGen, Inc.
  • Roche Holding AG
  • Genentech
  • Concortis Biotherapeutics
  • AGENSYS, INC.
  • Antikor
  • Immunomedics
  • Pfizer Inc.
  • Celldex Therapeutics
  • Millennium Pharmaceuticals
  • AbbVie Inc.
  • Bayer HealthCare
  • Astellas Pharma/Agensys
  • Progenics Pharmaceuticals
  • Mersana Therapeutics
  • Synthon
  • Heidelberg Pharma
  • Oxford BioTherapeutics

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Antibody Drug Conjugates Market:

  • In June 2022, For the creation of highly specialised ADCs for the treatment of solid tumours, Spirea Limited revealed that it has obtained GBP 2.4 million in financing from investors.
  • In December 2022, ImmunoGen Inc. and Biosion USA Inc.  collaborated to develop antibody drug conjugates (ADCs) for the treatment of cancer.

In recent years, the market for antibody drug conjugates (ADC) has grown drastically, and in the years to come, it is anticipated to increase steadily. ADCs are a family of targeted cancer medicines that combine the cytotoxicity of small molecule medications with the specificity of monoclonal antibodies. By the use of this special combination, cytotoxic medications is delivered to cancer cells only, causing the least amount of harm to healthy cells and exhibiting the fewest negative side effects. The quest for more efficient and individualised therapies along with the rising prevalence of cancer globally has been a key factor driving the ADC market. Also, a number of innovative ADCs have been created as a result of the expanding emphasis on research and development in the field of cancer, and their clinical trial outcomes have been encouraging.

ADC market expansion is also being fuelled by an increase in partnerships and cooperation between pharmaceutical firms and academic institutions. These partnerships have produced new technologies and production methods that have increased the productivity and affordability of making ADCs.

ADCs are expensive, and a complex manufacturing procedure is required to produce them, which limits the market's expansion. The complicated process of bringing new items to market is further complicated by the strict regulatory criteria for ADC clearance. The substantial advantages that ADCs provide over conventional cancer therapies are projected to drive market growth even in the presence of these obstacles. The price of ADCs is anticipated to reduce, making them more affordable for patients as technology advances and the production process is standardised.

By Type

  • Monoclonal Antibodies
  • Linker
  • Drug/Toxin
  • Others

By Application

  • Leukemia
    • Acute Myeloid Leukemia (AML)
    • Chronic Myeloid Leukemia (CML)
    • Acute Lymphocytic Leukemia (ALL)
    • Chronic Lymphocytic Leukemia (CLL)
  • Prostate Cancer
  • Kidney Cancer
  • Pancreas Cancer
  • Ovary Cancer
  • Glioblastoma
  • Lung Cancer
  • Colon Cancer
  • Breast Cancer
  • Skin Cancer
  • Solid Tumors
  • Multiple Myeloma
  • Lymphoma

By Product

  • Adcetris
  • Kadcyla
  • Others

By Technology

  • ImmunoGen Technology
  • Seattle Genetics Technology
  • Immunomedics Technology
  • Others

By End User

  • Hospitals
  • Specialized Cancer Centers
  • Academic Research Institutes
  • Biopharmaceutical Companies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Increasing cancer incidence and technology advancements are likely to cause North America to see considerable growth throughout the predicted period. Due to countries in the region, such as the United States, Mexico and Canada, making substantial technical strides, the region is expanding significantly. In terms of clinical information, North America is a fairly developed region, and the use of ADCs is taken into account for the majority share of the established industry. For instance, Pfizer purchased Amplyx Pharmaceuticals Inc. in April 2021 to create antibody drug conjugates and various additional cancer medicines. Additionally, based on application; breast cancer is the largest segment. By drug type, kadycla is the highest revenue share holding segment in the global market in 2022.


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Antibody Drug Conjugate Market By Type, By Application, By Product, By Technology, By End User and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antibody Drug Conjugate Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antibody Drug Conjugate Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antibody Drug Conjugate Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antibody Drug Conjugate Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Monoclonal Antibodies
        2. Linker
        3. Drug/Toxin
        4. Others

  • 8.   Antibody Drug Conjugate Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Leukemia
         1.1. Acute Myeloid Leukemia (AML)
         1.2. Chronic Myeloid Leukemia (CML)
         1.3. Acute Lymphocytic Leukemia (ALL)
         1.4. Chronic Lymphocytic Leukemia (CLL)
        2. Prostate Cancer
        3. Kidney Cancer
        4. Pancreas Cancer
        5. Ovary Cancer
        6. Glioblastoma
        7. Lung Cancer
        8. Colon Cancer
        9. Breast Cancer
        10. Skin Cancer
        11. Solid Tumors
        12. Multiple Myeloma
        13. Lymphoma

  • 9.   Antibody Drug Conjugate Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Adcetris
        2. Kadcyla
        3. Others

  • 10.   Antibody Drug Conjugate Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. ImmunoGen Technology
        2. Seattle Genetics Technology
        3. Immunomedics Technology
        4. Others

  • 11.   Antibody Drug Conjugate Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialized Cancer Centers
        3. Academic Research Institute
        4. Biopharmaceutical Companies
        5. Others

  • 12.   North America Antibody Drug Conjugate Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Antibody Drug Conjugate Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Antibody Drug Conjugate Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Antibody Drug Conjugate Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Seattle Genetics
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. ImmunoGen, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Roche Holding AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Genentech
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Concortis Biotherapeutics
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. AGENSYS, INC.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Antikor
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Immunomedics
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Pfizer Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Celldex Therapeutics
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Millennium Pharmaceuticals
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. AbbVie Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Bayer HealthCare
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Astellas Pharma/Agensys
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Progenics Pharmaceuticals
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Mersana Therapeutics
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Synthon
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Heidelberg Pharma
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Oxford BioTherapeutics
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients